DeepMed Research

Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Bendamustine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 332

Registration Number: NCT05899621

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma
Transformed Non-Hodgkin Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Biological: Tafasitamab
Other: Questionnaire Administration
Drug: Tazemetostat
Drug: Zanubrutinib

First Posted Date: 2023-06-06

Last Posted Date: 2024-10-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 227

Registration Number: NCT05890352

Locations: 🇺🇸
SWOG, Portland, Oregon, United States
🇺🇸
Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
🇺🇸
Saint Joseph Mercy Brighton, Brighton, Michigan, United States

and more 8 locations

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Phase 3

Recruiting

Conditions: Follicular Lymphoma (FL)

Interventions: Biological: Tisagenlecleucel
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
Drug: Lymphodepleting chemotherapy
Other: Corticosteroids and/or Radiation (Bridging therapy)

First Posted Date: 2023-06-05

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT05888493

Locations: 🇺🇸
TRIHEALTH Good Samarithan Hospital, Cincinnati, Ohio, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1

Withdrawn

Conditions: Follicular Lymphoma

Interventions: Drug: rituximab
Drug: lenalidomide
Drug: parsaclisib

First Posted Date: 2023-05-19

Last Posted Date: 2023-10-17

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Registration Number: NCT05867030

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Phase 1

Recruiting

Conditions: Blastoid Variant Mantle Cell Lymphoma
Mantle Cell Lymphoma
Pleomorphic Variant Mantle Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Glofitamab
Drug: Lenalidomide
Biological: Obinutuzumab
Procedure: Positron Emission Tomography
Drug: Venetoclax

First Posted Date: 2023-05-16

Last Posted Date: 2025-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 50

Registration Number: NCT05861050

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: High-Risk de Novo Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Teclistamab
Drug: Talquetamab

First Posted Date: 2023-05-09

Last Posted Date: 2025-03-19

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 30

Registration Number: NCT05849610

Locations: 🇪🇸
Hospital Germans Trials i Pujol, Badalona, Spain
🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
🇪🇸
Hospital Doce de Octubre, Madrid, Spain

and more 7 locations

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Phase 2

Recruiting

Conditions: Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Drug: Epcoritamab
Drug: Investigation agent 2
Drug: Investigation agent 3
Drug: Lenalidomide
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustine
Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2023-05-08

Last Posted Date: 2023-11-29

Lead Sponsor: University of Birmingham

Target Recruit Count: 284

Registration Number: NCT05848765

Locations: 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧
Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧
NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2

Recruiting

Conditions: Marginal Zone Lymphoma

Interventions: Drug: Obinutuzumab
Drug: lenalidomide

First Posted Date: 2023-05-06

Last Posted Date: 2023-07-19

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 59

Registration Number: NCT05846750

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tian, China

VitD3 Supplementation in Patients With Multiple Myeloma

Early Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Maintenance Vitamin D
Drug: No maintenance Vitamin D

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-08

Lead Sponsor: Amany Keruakous, MD, MS.

Target Recruit Count: 100

Registration Number: NCT05846880

Locations: 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

Phase 2

Not yet recruiting

Conditions: Advanced HCC

Interventions: Drug: Lenalidomide

First Posted Date: 2023-04-26

Last Posted Date: 2023-04-26

Lead Sponsor: Shenyang Tenth People's Hospital

Target Recruit Count: 23

Registration Number: NCT05831969

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy